NCT06961370 - A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) | Biotech Hunter

Enrollment

132

Participants

Timeline

Start Date

July 16, 2025

Primary Completion Date

January 3, 2027

Study Completion Date

January 3, 2027

Conditions

Geographic AtrophyAge-related Macular Degeneration

Interventions

DRUG

RO7669330

RO7669330 will be administered as an IVT injection in the study eye per the schedule specified in the respective arms.

DRUG

Syfovre™

Syfovre™ will be administered as an IVT injection in the study eye per the schedule specified in the respective arms.

DRUG

Izervay™

Izervay™ will be administered as an IVT injection in the study eye per the schedule specified in the respective arms.

Trial Locations (16)

16505

RECRUITING

Erie Retina Research, Erie

21740

RECRUITING

Cumberland Valley Retina Consultants PC, Hagerstown

30909

RECRUITING

Southeast Retina Center, Augusta

37203

RECRUITING

Tennessee Retina PC, Nashville

38138

RECRUITING

Charles Retina Institute, Germantown

63128

RECRUITING

The Retina Institute, St Louis

75231

RECRUITING

Texas Retina Associates, Dallas

77384

RECRUITING

Retina Consultants of Texas - (The Woodlands), The Woodlands

78251

RECRUITING

Retina Consultants of Texas Westover Hills Retina Center, San Antonio

78750

RECRUITING

Austin Clinical Research, LLC, Austin

85351

RECRUITING

Barnet Dulaney Perkins Eye Center, Sun City

90211

RECRUITING

Retina-Vitreous Associates Medical Group, Beverly Hills

91204

RECRUITING

Global Research Management, Glendale

95825

RECRUITING

Retinal Consultants Medical Group Inc - Parkcenter Drive, Sacramento

97221

RECRUITING

Retina Northwest, Portland

85020-5505

RECRUITING

Associated Retina Consultants - Phoenix - DocTrials - PPDS, Phoenix

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY